mt-3921
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2019 (NCT04096950)
Timeline
Indications
Mechanism of action
- Repulsive guidance molecule AINHIBITOR
RGMA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05396235 | Phase 1 | Aug 3, 2022 | Mitsubishi Tanabe |
| NCT05240612 | Phase 1 | May 2, 2022 | Mitsubishi Tanabe |
| NCT04683848 | Phase 2 | Jun 30, 2021 | Mitsubishi Tanabe |
| NCT04096950 | Phase 1 | Oct 31, 2019 | Mitsubishi Tanabe |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mitsubishi Tanabe | For profit | 4 | 4 | 2 | 2019 |
1 organizations
Page 1 / 1